1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Biovica International AB (publ)
  6. News
  7. Summary
    BIOVIC B   SE0008613731

BIOVICA INTERNATIONAL AB (PUBL)

(BIOVIC B)
  Report
Delayed Quote. Delayed Nasdaq Stockholm - 05/27 11:29:33 am
37.75 SEK   +8.63%
05/17TRANSCRIPT : Biovica International AB - Analyst/Investor Day
CI
05/09Biovica's DiviTum«TKa at ASCO
AQ
04/28Biovica completes 510(k) submission for DiviTum«TKa to the FDA
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Biovica's DiviTum«TKa in three studies at SABCS 2021

11/19/2021 | 10:06am EDT

Biovica, active in cancer diagnostics, today announced that results from three different studies using DiviTum®TKa, including a budget impact model, will be presented at the world's largest breast cancer symposium, San Antonio Breast Cancer Symposium (SABCS), in early December. The studies are of a next generation CDK inhibitor, samuraciclib from Carrick Therapeutics, the biomarker study PROMISE performed at the Mayo Clinic, and the DiviTum®TKa budget impact model. All studies focused on the role of DiviTum®TKa in monitoring treatment in women with metastatic breast cancer.

Biovica and Carrick Therapeutics have collaborated on generating TK activity (TKa) data in the phase 1/2A study of samuraciclib (NCT033638939), a first-in-class, oral, selective inhibitor of CDK7 that recently received fast track designation from the US Food and Drug Administration (FDA). The study demonstrates the potential association of TKa levels with treatment effect for this next generation CDK inhibitor.
P1-18-10 A clinical study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced triple negative breast cancer (TNBC)

DiviTum®TKa results from the clinical study PROMISE (NCT03281902) conducted at the Mayo Clinic show the association of TKa with progression free survival. The study results are a continuation of the results presented on SABCS 2020. Since then, the study has continued and samples from almost twice as many patients have been tested for TKa, with the new results confirming the initial analysis and earlier DiviTum®TKa results – i.e., the usage of DiviTum®TKa as a valuable tool in the evaluation of treatment effect in metastatic breast cancer.
P5-13-22 Serum thymidine kinase 1 activity (TKa) levels and progression-free survival (PFS) in patients (pts) with hormone receptor positive (HR+) HER2-negative metastatic breast cancer (MBC) on palbociclib (Pb) and endocrine therapy (ET)

Additional results of the healthcare DiviTum®TKa Budget Impact Model show the potential for DiviTum®TKa to substantially reduce the number of CT scans and bone scans used in monitoring women with metastatic breast cancer. As these scans are both costly and a burden on patients, this reinforces the potential benefit of DiviTum®TKa to healthcare systems and to patients. Additionally, the test may enable early identification when a treatment is not effective and therefore enable overall savings of three times the added spend on the DiviTum®TKa test.
P3-03-05 The budget impact of the DiviTum®TKa assay in postmenopausal women with hormone receptor positive metastatic breast cancer

“The data on DiviTum®TKa being presented at SABCS strengthens the scientific and economic foundation for the role of the test in the care of breast cancer patients. We are very pleased with these results,” said Anders Rylander, CEO of Biovica.

The San Antonio Breast Cancer Symposium, SABCS, runs December 7-10, 2021.

© Modular Finance, source Nordic Press Releases

All news about BIOVICA INTERNATIONAL AB (PUBL)
05/17TRANSCRIPT : Biovica International AB - Analyst/Investor Day
CI
05/09Biovica's DiviTum«TKa at ASCO
AQ
04/28Biovica completes 510(k) submission for DiviTum«TKa to the FDA
AQ
04/28Biovica completes 510(k) submission for DiviTum«TKa to the FDA
CI
04/28Biovica Capital Markets Day invitation May 17, 2022
AQ
03/22Positive DiviTum«TKa results published in npj Breast Cancer
AQ
03/15TRANSCRIPT : Biovica International AB, Q3 2022 Earnings Call, Mar 15, 2022
CI
03/15Biovica International AB Provides Earnings Guidance for the Full Year 2022
CI
03/15Biovica International AB Reports Earnings Results for the Third Quarter and Nine Months..
CI
03/14Biovica establishes US CLIA lab to further strengthen DiviTum«TKa launch
AQ
More news
Financials
Sales 2022 1,00 M 0,10 M 0,10 M
Net income 2022 -37,1 M -3,77 M -3,77 M
Net cash 2022 120 M 12,2 M 12,2 M
P/E ratio 2022 -19,6x
Yield 2022 -
Capitalization 1 075 M 109 M 109 M
EV / Sales 2022 955x
EV / Sales 2023 5,68x
Nbr of Employees 26
Free-Float 42,9%
Chart BIOVICA INTERNATIONAL AB (PUBL)
Duration : Period :
Biovica International AB (publ) Technical Analysis Chart | BIOVIC B | SE0008613731 | MarketScreener
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 37,75
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Anders Rylander Chief Executive Officer & Director
Cecilia Driving Chief Financial Officer, Executive VP & IR Contact
Lars Erik Holmqvist Chairman
Otti Bengtsson Gref Vice President-Research & Development
Tomas Andersson Vice President-Operations
Sector and Competitors